针治疗肥胖症:一个总体评论
Min Chen1, RuiRui Wu2, Rui Chen3
1Department of Traditional Chinese Medicine, The Third People's Hospital of Chengdu, Chengdu, China.
Journal of evidence-based medicine
|October 10, 2025
概括
高质量的证据支持针治疗肥胖症,特别是在改变生活方式的同时. 它比没有治疗和假针更有好处,是药物可行的替代品.
科学领域:
- 综合医学是一个整体医学.
- 基于证据的实践.
- 肥胖问题研究研究
背景情况:
- 关于针治疗肥胖的有效性存在相互矛盾的发现.
- 在肥胖管理中针的证据的确定性尚不清楚.
- 本综合性审查旨在澄清针对身体质量指数 (BMI) 和体重 (BW) 影响的高质量证据.
研究的目的:
- 评估现有的关于针治疗肥胖症的系统审查.
- 通过高质量的证据来确定对BMI和BW的影响.
- 为指导治疗肥胖症中针的临床建议.
主要方法:
- 针对肥胖症针的随机对照试验 (RCT) 系统审查的总体综述.
- 在PubMed,Embase和Cochrane图书馆进行的搜索截至2025年4月28日.
- 使用AMSTAR评估的方法质量;使用GRADE评估的证据质量.
主要成果:
- 包括22个系统审查 (60个元分析);17个具有高的方法质量.
- 五项元分析显示,针对BMI和BW的益处有高质量的证据.
- 最强有力的证据支持针加生活方式干预与单独生活方式干预.
结论:
- 临床医生可以推针治疗肥胖症,特别是作为生活方式干预的辅助疗法.
- 针对于不能容忍药物治疗的患者来说是一个合理的替代方案.
- 最佳的效益需要与全面的生活方式修改进行整合,而不是独立使用.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...